A Phase III Randomized Study of Imatinib, With or Without Bevacizumab (NSC-704865), in Patients With Metastatic or Unresectable Gastrointestinal Stromal Tumors.
Latest Information Update: 18 Sep 2021
Price :
$35 *
At a glance
- Drugs Bevacizumab (Primary) ; Imatinib
- Indications Gastrointestinal stromal tumours
- Focus Therapeutic Use
- 14 Sep 2017 Biomarkers information updated
- 04 Jan 2013 Planned end date (Apr 2014) added as reported by ClinicalTrials.gov.
- 12 Jun 2012 Actual patient number is 12 as reported by ClinicalTrials.gov.